Immuno-Oncology | Specialty

IDO Inhibitor Increases Pembrolizumab Response in Melanoma

April 4th 2017

Adding the IDO inhibitor indoximod to pembrolizumab led to an overall response rate of 52% in patients with advanced melanoma, according to findings from a phase II trial reported at the 2017 AACR Annual Meeting.

Adding Coxsackievirus to Ipilimumab Displays Durable Antitumor Activity in Advanced Melanoma

April 4th 2017

Adding a formulation of the Coxsackievirus A21 (CAVATAK®) to ipilimumab (Yervoy) yielded an overall response rate of 50% and was well-tolerated in immunotherapy-naïve and pretreated patients with advanced melanoma.

Dr. Brahmer on 5-Year Follow-Up Data for Nivolumab in NSCLC

April 4th 2017

Julie R. Brahmer, MD, associate professor of Oncology, Bloomberg Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, discusses 5-year follow-up data from the CA209-003 study of nivolumab in previously treated advanced non-small cell lung cancer (NSCLC).

Dr. Luke Discusses the Controversy Surrounding Ipilimumab/Nivolumab Combo in Melanoma

April 3rd 2017

Jason J. Luke, MD, assistant professor of Medicine, The University of Chicago Medicine, discusses the controversy surrounding the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in treatment-naïve patients with advanced melanoma, which was explored in the CheckMate-067 trial, during the AACR Annual Meeting.

Five-Year Survival Rate an Impressive 16% With Nivolumab in Advanced NSCLC

April 3rd 2017

Long-term survival in patients with metastatic non–small cell lung cancer who received the immune checkpoint inhibitor nivolumab (Opdivo) has proven to be much higher than expected, with 16% of these patients surviving after 5 years, equivalent to about 4 times what would be expected with chemotherapy.

Nivolumab/Ipilimumab Combo Shows Modest OS Benefit in Advanced Melanoma in Updated Phase III Findings

April 3rd 2017

The PD-1 and CTLA-4 inhibitor combination of nivolumab (Opdivo) and ipilimumab (Yervoy) was associated with a 12% reduction in the risk of death versus nivolumab monotherapy in patients with treatment-naïve advanced melanoma.

Avelumab Further Demonstrates Durable Responses in Merkel Cell Carcinoma

April 3rd 2017

Treatment with the PD-L1 inhibitor avelumab induced an objective response rate of 33% in patients with advanced Merkel cell carcinoma in the phase II JAVELIN Merkel 200 study, including 2 additional complete responses since the primary analysis.

Atezolizumab Yields Long-Term OS in mTNBC Subset

April 3rd 2017

According to results presented at the 2017 AACR Annual Meeting, 10% of patients showed impressive long-term survival in a phase I study of single agent anti-PD-L1 atezolizumab (Tecentriq) in patients with metastatic triple-negative breast cancer.

Novel Agents Continue to Make Mark in Lung Cancer

March 30th 2017

Mark B. Stoopler, MD, discusses ongoing developments in immunotherapy and his vision for the future of non-small cell lung cancer treatment.

Dr. Turaga on Surgery Versus Immunotherapy in Melanoma

March 30th 2017

Kiran K. Turaga, MD, associate professor of surgery, vice chief, section of general surgery and surgical oncology, director of the Surgical GI Cancer Program and the Regional Therapeutics Program at The University of Chicago Medicine, discusses whether patients vie for immunotherapy versus surgery as treatment for their melanoma.

Frontline Immunotherapy on the Horizon in Bladder Cancer

March 29th 2017

Evan Y. Yu, MD, discusses the current treatment options for patients with metastatic urothelial carcinoma, the unmet needs that still exist in this space, and the possibilities for the future treatment landscape.

Efforts Continue to Introduce Immunotherapy Into Earlier NSCLC Settings

March 28th 2017

Daniel Costin, MD, shares insight on understanding the deeper biology of the immune system, the emerging research with immunotherapy, and the importance of managing associated adverse events.

Dr. Drilon on Immunotherapy in Lung Cancer

March 28th 2017

Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses immunotherapy in patients with lung cancer.

Dr. Papadimitrakopoulou on Immunotherapy Combinations in Lung Cancer

March 28th 2017

Vassiliki A. Papadimitrakopoulou, MD, professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses trials investigating combinations of immunotherapy regimens in lung cancer.

Dr. Gajewski on Targets Being Explored in Melanoma

March 28th 2017

Thomas F. Gajewski, MD, PhD, professor of medicine at The University of Chicago Medicine, discusses what targets are currently being explored in patients with melanoma.

Expert Tackles Efficacy of PD-L1 Testing for NSCLC in 2017

March 28th 2017

Daniel B. Costa, MD, PhD, discusses biomarker testing in non-small cell lung cancer and the necessary next steps for PD-L1 testing.

Dr. Spigel on Pembrolizumab/Chemo Combo in First-Line NSCLC

March 27th 2017

David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the results of cohort G from the KEYNOTE-021 trial, which explored pembrolizumab (Keytruda) combined with pemetrexed/carboplatin as a frontline treatment for patients with nonsquamous non–small cell lung cancer (NSCLC).

Dr. Jagannath on Potential of Immunotherapy in Multiple Myeloma

March 27th 2017

Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai Cancer Center, discusses the potential impact of immunotherapy in multiple myeloma.

Expert Provides Perspective on Immunotherapy Advances in Lung Cancer

March 27th 2017

Jared Weiss, MD, offers his expert insight into the actual impact of the immunotherapy advances in lung cancer.

Pembrolizumab Recommended for EU Approval in Hodgkin Lymphoma

March 25th 2017

The EMA’s Committee for Medicinal Products for Human Use has recommended approval of pembrolizumab for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma who have progressed following autologous stem cell transplant and brentuximab vedotin, or who are transplant-ineligible and have failed brentuximab vedotin.